CFN Media Group (“CannabisFN”), the leading creative agency and media network dedicated to legal cannabis, announces publication of an article covering Harvest One Cannabis Inc.’s (TSXV:HVT) new plans to lease and retrofit an existing timber facility to accelerate its cannabis commercialization timeline. The article also discusses Harvest One’s subsidiary Satipharm AG and its progress in advancing clinical trials of its proprietary Gelpell® delivery system for cannabinoids in the treatment of children’s refractory epilepsy.
New Letter of Intent
Harvest One Cannabis recently announced that its wholly-owned subsidiary, United Greeneries Ltd., has entered into a letter of intent with a third party for the lease of a property in Chemainus, BC to accelerate and expand production capacity. As a previous industrial lumber kiln drying plant, the facility has an industrial power supply and usable building envelopes. The team has already begun detailed design work and commenced licensing integration activities.
“The Chemainus Facility will allow United Greeneries to capitalize on supplying the upcoming recreational market in Canada with large volumes of high quality dried cannabis buds,” said Harvest One Cannabis CEO Andreas Gedeon. “The company is committed to aggressively pursuing the opportunities at hand and to continue its successful approach of providing shareholders with targeted and substantial value in this thriving industry.”
Management believes that it will be able to commence cultivation activities next year with an initial annual capacity of approximately 8,000 kilograms. In terms of capital expenditure, the team anticipates covering the retrofitting costs with its current cash balance without need for additional financing. The LOI also provides UG with a lease option on a further eight acres on the site, which could be developed to ultimately produce more than 35,000 kilograms per year on a full build out and expansion basis.
A Better Alternative
Harvest One Cannabis’ previously planned Duncan facility expansion would have been a greenhouse operation that would have taken longer to commercialize than the Chemainus Facility. In addition to its shortened timetable, the Chemainus Facility will be an indoor growing environment capable of producing higher quality cannabis instead of extraction grade greenhouse cannabis. This could open the door to higher margin opportunities than were previously possible.
The Duncan facility, with its 1,000-kilogram current annual capacity, will remain as a base of operations for the company on Vancouver Island with a focus on increasing capacity through an expansion plan at the nearby Chemainus Facility. The existing facility’s proximity to the new facility is beneficial, as the two locations will complement each other as United Greeneries’ business grows.
Additional Potential
United Greeneries may be focused squarely on cultivation, but Harvest One Cannabis also owns Satipharm AG to provide exposure to the medical side of the business.
Earlier this month, Satipharm AG announced positive Phase I clinical trial results in Israel using its proprietary Gelpell® technology. The results demonstrated the safety and performance of the oral capsule technology, including the effective delivery profile of cannabidiol (CBD) compound to trial subjects. The trial also highlighted the favorable bioavailability of the capsules compared to Sativex – a market leading oral cannabinoid spray from GW Pharmaceuticals plc (GWPH).
The company has since begun Phase II clinical trials to evaluate the efficacy of Satipharm’s capsules in treating refractory epilepsy in children. The completion of the Phase II clinical trial would be a major catalyst toward commercialization of the capsules. In fact, the company could become just the third company to complete Phase II clinical trials next to GW Pharmaceuticals plc and Insys Therapeutics Inc. for refractory epilepsy in children.
Please follow the link to read the full article: http://www.cannabisfn.com/harvest-one-cannabis-takes-faster-route-commercialization/
For more information, visit the company’s website at www.harvestone.com.
About CFN Media
CFN Media (CannabisFN) is the leading creative agency and media network dedicated to legal cannabis. We help marijuana businesses attract investors, customers (B2B, B2C), capital, and media visibility. Private and public marijuana companies and brands in the US and Canada rely on CFN Media to grow and succeed.
 
Disclaimer:
Except for the historical information presented herein, matters discussed in this release contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Emerging Growth LLC, which owns CFN Media and CannabisFN.com, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. Emerging Growth LLC may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. Emerging Growth LLC may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. For full disclosure please visit: http://www.cannabisfn.com/legal-disclaimer/
Click here to connect with Harvest One Cannabis Inc. (TSXV:HVT) for an Investor Presentation

Source: www.newsfilecorp.com


Centurion to acquire a Disruptive Water-Soluble Cannabinoid Technology Platform Delivering Rapid Onset, Increased Bioavailability, Premium Taste Profiles and Highly Competitive Cost Structure

Centurion Minerals Ltd. (TSXV: CTN) (FSE: XJCB) (“Centurion” or the “Company”) is pleased to announce that it has entered into an Amalgamation Agreement dated February 17, 2021 (the “Agreement”), with HAI Beverages Inc. (“HAI”), whereby Centurion will acquire 100% of the outstanding shares and assets of a wholly-owned subsidiary of HAI (“NewHAI) in exchange for common shares of Centurion (the “Acquisition” or “Transaction”). NewHAI holds all material assets of HAI and the Acquisition will constitute a reverse take-over (“RTO”) of the Company.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today its participation in the following investor conferences:

  • Needham 2nd Annual Virtual Cannabis Conference – March 3 rd , 2021 – Management will participate in virtual one-on-one meetings.
  • 33rd Annual Roth Conference – March 15 th -17 th , 2021 – Charlie Bachtell, CEO and Co-Founder, will participate in a Fireside Chat and management will later participate in virtual one-on-one meetings on April 7 th .
  • Stifel Multi-Sector Conference – April 21 st , 2021 – Management will participate in virtual one-on-one meetings.

About Cresco Labs

Keep reading... Show less

Green Thumb Industries, a leading cannabis consumer packaged goods company and owner of Rise™ Dispensaries, is expanding key partnerships and creating scholarships earmarked for those from communities most impacted by the war on drugs as part of its corporate social responsibility program. The scholarships will be granted to a total of four students for programs at the Cleveland School of Cannabis in Ohio and Olive-Harvey College in Illinois. Additionally, Green Thumb will continue its support of Cabrini Green Legal Aid and partner with the North Lawndale Employment Network in Chicago as part of ongoing collaborations that include financial support, volunteerism and awareness initiatives.

Building on the foundation of Green Thumb’s LEAP initiative, which provided pro-bono support for social equity license applicants in Illinois and which will soon offer business incubator resources to newly awarded social equity entrepreneurs, these impactful partnerships mark a critical next step in prioritizing diversity, equity, and inclusion in the cannabis industry.

Keep reading... Show less

All five flavours of the Company’s KOIOS™ nootropic beverage product are now being carried by Jensen’s, a regional supermarket chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. This placement of KOIOS™ follows several other recent placements of the Company’s beverage products in regional supermarket chains across the United States as part of a strategy to passively build market share in specific geographical areas.

Koios Beverage Corp. (CSE: KBEV; OTC: KBEVF) (the “Company” or “Koios”) is pleased to announce that the full range of five flavours of its KOIOS ™ nootropic beverages can now be purchased at all grocery stores operated by Jensen’s Foods (“Jensen’s”), a long-established family-owned grocery chain operating in the San Diego, Los Angeles, and Palm Springs areas of Southern California. In a press release dated February 19, 2021 the Company announced another chain-wide placement of KOIOS ™ nootropic beverages on the west coast of the United States with Market of Choice in Oregon. With this placement of KOIOS ™ in Jensen’s supermarkets, the Company’s beverage products are now carried in approximately 180 retail stores on the west coast, out of a total of more than 4,000 retail stores nationwide.

Keep reading... Show less

 Lobe Sciences Ltd. (CSE: LOBE) (OTC Pink: GTSIF) (“Lobe” or the “Company”) announces that Philip Young, CEO and Director, and Maghsoud Dariani, Chief Science Officer will be presenting on Thursday, February 25th, 2021 at 5:45 pm EST at “The Gold Standard in Psychedelic Investment, Psychedelic Capital Virtual Investment Conference”, a platform showcasing the top companies, latest IPOs, newest opportunities, and deepest industry insights.

As a presenting sponsor, the Company will connect directly with some of the earliest moving investors in the psychedelic industry and reach an audience of 2,000+ investors. Presentations are 30 minutes in length, with 10 minutes allocated to a one-on-one Q&A session with the audience.

Keep reading... Show less